SUVN G3031

Drug Profile

SUVN G3031

Alternative Names: SUVN-G3031

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suven Life Sciences
  • Class Neuropsychotherapeutics; Nootropics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 16 Nov 2017 Suven Life Sciences has patent protection for selective serotonin (H3 and 5-HT6) compounds for neurodegenerative disorders in USA, Hong Kong and India
  • 18 Oct 2017 SUVN G3031 is at phase I development stage for Cognition disorders in USA (PO)
  • 01 Sep 2017 Suven Life Sciences completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02881294)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top